advertisement
Abstract #47833 Published in IGR 13-4
Longer term patient benefits of polyquad(registered trademark) preservative instead of benzalkonium chloride in prostaglandin eye drops: A microsimulation model in ocular hypertension and open-angle glaucoma
Gerlier L; Lamotte M; Berdeaux G; Verboven Y; Pfeiffer NValue in Health 2011; 14: A502
OBJECTIVES: The presence of the preservative benzalkonium chloride (BAK) at 0.01% concentration in commercialized prostaglandin eye drops for glaucoma is known to increase the risk of ocular surface disease (OSD), which worsens with the extent of exposure to BAK. We aimed to estimate longer term clinical outcomes with travoprost preserved with Polyquad(registered trademark) 0.001% instead of BAK. METHODS: A Markov microsimulation model was developed (TreeAge) to assess the development of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in patients initiating travoprost with Polyquad(registered trademark) followed by travoprost/beta-blocker fixed combination vs. the same sequence using BAK-preserved drops. Initial patient's characteristics came from distributions on age (normal), sex, OSD presence, disease stage (uniform) and anticipated progression rates (triangular). The risk of developing OSD in aging population was derived from a US incidence study, multiplied by independent risk factors (age, sex, duration and amount of BAK-containing drops received). Rates of disease progression (db/year) came from landmark studies in OHT/glaucoma, multiplied by independent accelerating factors (disease stage, treatment line, OSD severity, non-compliance). Compliance was expected by experts to be 20% (absolute) better with Polyquad(registered trademark) vs. BAK-preserved drops. RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD, mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line BAK-preserved travoprost treatments are expected to have OSD at 10 years versus 31.7% [28.5-35.1%] with Polyquad(registered trademark). In OHT/early glaucoma patients, the model predicted the progression to advanced glaucoma (MD<-12db) of 13.2% [12.0-14.4%] with Polyquad(registered trademark) versus 18.1% [16.7-19.5%] with BAK. In patients diagnosed with moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness (MD<-24db) respectively. CONCLUSIONS: The model estimated that OSD incidence was reduced by 33% and glaucoma disease progression was significantly less frequent after 10 years of use of Polyquad(registered trademark) versus BAK-containing travoprost eye drops.
L. Gerlier. IMS Consulting Group, Vilvoorde, Belgium.
Classification:
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
11.4 Prostaglandins (Part of: 11 Medical treatment)
